NZ720287A - Pharmaceutical compositions comprising dimethyl fumarate - Google Patents

Pharmaceutical compositions comprising dimethyl fumarate

Info

Publication number
NZ720287A
NZ720287A NZ720287A NZ72028714A NZ720287A NZ 720287 A NZ720287 A NZ 720287A NZ 720287 A NZ720287 A NZ 720287A NZ 72028714 A NZ72028714 A NZ 72028714A NZ 720287 A NZ720287 A NZ 720287A
Authority
NZ
New Zealand
Prior art keywords
dimethyl fumarate
pharmaceutical compositions
starch
compositions
gastro
Prior art date
Application number
NZ720287A
Other languages
English (en)
Inventor
Jimenez Maria Planells
Lopez Begoña Duarte
Coll Pere Guiro
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ720287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Priority to NZ759411A priority Critical patent/NZ759411A/en
Publication of NZ720287A publication Critical patent/NZ720287A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ720287A 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate NZ720287A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ759411A NZ759411A (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382504 2013-12-12
PCT/EP2014/076767 WO2015086467A1 (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Publications (1)

Publication Number Publication Date
NZ720287A true NZ720287A (en) 2020-05-29

Family

ID=49917530

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ720287A NZ720287A (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate
NZ759411A NZ759411A (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ759411A NZ759411A (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Country Status (31)

Country Link
US (2) US20160310457A1 (https=)
EP (2) EP3656379A1 (https=)
JP (3) JP6581088B2 (https=)
KR (2) KR102335289B1 (https=)
CN (2) CN114159421B (https=)
AR (1) AR098746A1 (https=)
AU (2) AU2014363792B2 (https=)
BR (1) BR112016012179B1 (https=)
CA (2) CA2932054C (https=)
CL (1) CL2016001415A1 (https=)
CY (1) CY1124336T1 (https=)
DK (1) DK3079666T3 (https=)
EA (1) EA201600457A1 (https=)
ES (1) ES2860551T3 (https=)
HR (1) HRP20210468T1 (https=)
HU (1) HUE054408T2 (https=)
IL (2) IL287109B (https=)
LT (1) LT3079666T (https=)
MX (2) MX375144B (https=)
MY (1) MY179355A (https=)
NZ (2) NZ720287A (https=)
PH (2) PH12016501043B1 (https=)
PL (1) PL3079666T3 (https=)
PT (1) PT3079666T (https=)
RS (1) RS61658B1 (https=)
SG (3) SG10201802815UA (https=)
SI (1) SI3079666T1 (https=)
SM (1) SMT202100205T1 (https=)
TW (2) TWI704915B (https=)
UA (2) UA120428C2 (https=)
WO (1) WO2015086467A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
WO2016194004A1 (en) * 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
WO2017040272A1 (en) * 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
EP3397247B1 (en) * 2015-12-31 2023-06-07 Zaklady Farmaceutyczne Polpharma SA Process for preparation of an enteric coated granulate comprising dimethyl fumarate
PL3407873T3 (pl) * 2016-01-28 2025-01-13 Zakłady Farmaceutyczne POLPHARMA S.A. Sposób otrzymywania granulatu zawierającego fumaran dimetylu
JP2019510743A (ja) * 2016-02-12 2019-04-18 ウニヴェルズィテート チューリッヒ 痛風、ざ瘡及び糖尿病の予防又は治療のためのジメチルフマレート(dmf)
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
KR20200018458A (ko) 2017-06-23 2020-02-19 알미랄, 에스.에이. 디메틸 푸마레이트를 포함하는 약학 조성물
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020053218A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020053219A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
AU2020283238B2 (en) * 2019-05-31 2022-07-07 Curacle Co., Ltd. Enteric tablet containing dimethyl fumarate
JP6744518B1 (ja) * 2019-11-07 2020-08-19 旭化成株式会社 セルロース組成物及び錠剤
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
US12138351B2 (en) * 2020-04-14 2024-11-12 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
WO2022203432A1 (ko) * 2021-03-25 2022-09-29 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
EP4313023A1 (en) * 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2024232931A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and method for contact free delivery and administration of magnesium as a drug
WO2025235457A1 (en) 2024-05-09 2025-11-13 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
PL2316430T3 (pl) * 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1877059B8 (en) * 2005-04-28 2010-05-19 Wyeth a Corporation of the State of Delaware Micronized tanaproget and compostions containing same
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
EP2379062A1 (en) 2009-01-09 2011-10-26 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
CN102369001A (zh) 2009-01-09 2012-03-07 前进制药公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
JP2012525385A (ja) * 2009-04-29 2012-10-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経変性および神経炎症の治療
US20120308562A1 (en) * 2011-06-03 2012-12-06 Derynck Mika K Methods of treating mesothelioma with a pi3k inhibitor compound
WO2013076216A1 (en) 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
CN114146081A (zh) * 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物

Also Published As

Publication number Publication date
CA2932054C (en) 2022-09-20
LT3079666T (lt) 2021-03-25
SMT202100205T1 (it) 2021-07-12
MX2016007105A (es) 2016-08-11
TWI704915B (zh) 2020-09-21
ES2860551T3 (es) 2021-10-05
EP3079666A1 (en) 2016-10-19
US20210330628A1 (en) 2021-10-28
IL287109A (en) 2021-12-01
SI3079666T1 (sl) 2021-04-30
SG10201913080VA (en) 2020-03-30
AU2019268075A1 (en) 2019-12-12
MY179355A (en) 2020-11-05
JP6945603B2 (ja) 2021-10-06
DK3079666T3 (da) 2021-03-22
MX2020009745A (es) 2020-10-08
KR20160089397A (ko) 2016-07-27
SG10201802815UA (en) 2018-05-30
PT3079666T (pt) 2021-02-18
CY1124336T1 (el) 2022-07-22
BR112016012179A2 (https=) 2017-08-08
IL245685A0 (en) 2016-06-30
JP2016540003A (ja) 2016-12-22
TW202011953A (zh) 2020-04-01
UA123880C2 (uk) 2021-06-16
CN105813634A (zh) 2016-07-27
IL287109B (en) 2022-08-01
KR102335289B1 (ko) 2021-12-06
CA2932054A1 (en) 2015-06-18
JP2019218385A (ja) 2019-12-26
IL245685B (en) 2021-10-31
JP2021130689A (ja) 2021-09-09
HUE054408T2 (hu) 2021-09-28
EP3079666B1 (en) 2021-02-03
MX375144B (es) 2025-03-06
HK1224212A1 (en) 2017-08-18
CA3135273A1 (en) 2015-06-18
CL2016001415A1 (es) 2017-01-20
PH12019502610A1 (en) 2021-02-22
KR20210150587A (ko) 2021-12-10
JP6581088B2 (ja) 2019-09-25
UA120428C2 (uk) 2019-12-10
PH12016501043A1 (en) 2016-07-04
TWI687218B (zh) 2020-03-11
CN114159421A (zh) 2022-03-11
PL3079666T3 (pl) 2021-09-06
KR102353201B1 (ko) 2022-01-18
TW201605435A (zh) 2016-02-16
EP3656379A1 (en) 2020-05-27
AU2014363792A1 (en) 2016-06-09
SG10201913076PA (en) 2020-02-27
CN114159421B (zh) 2023-08-25
AU2014363792B2 (en) 2019-11-14
BR112016012179B1 (pt) 2023-04-18
RS61658B1 (sr) 2021-04-29
HRP20210468T1 (hr) 2021-05-14
WO2015086467A1 (en) 2015-06-18
EA201600457A1 (ru) 2016-11-30
PH12016501043B1 (en) 2016-07-04
AU2019268075B2 (en) 2020-12-17
NZ759411A (en) 2020-06-26
US20160310457A1 (en) 2016-10-27
AR098746A1 (es) 2016-06-08

Similar Documents

Publication Publication Date Title
PH12019502610A1 (en) Pharmaceutical compositions comprising dimenthyl fumarate
HUE054389T2 (hu) Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP4349406A3 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
GB2547397A (en) Configuration based cache coherency protocol selection
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
EA201790785A1 (ru) Производные тетрагидроизохинолина
BR112017001758A2 (pt) álcoois polivinílicos diretamente compressíveis
SI3210973T1 (sl) Heteroarilne spojine za zdravljenje oftalmičnih bolezni
EP3406184A4 (en) PROCESSOR FOR ENDOSCOPE
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
WO2017008033A8 (en) Pyrrolidine carboxamido derivatives and methods for preparing and using the same
EP3080139A4 (en) A process for the preparation of regadenoson
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
EP3033053A4 (en) Bioresorbable scaffold for treatment of bifurcation lesion
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
PH12015502703A1 (en) Pharmaceutical compositions
EP3189847A4 (en) Therapeutic or prophylactic agent for itching skin diseases
HK40019968A (en) Dosage forms of tissue kallikrein 1
HK1216150A1 (zh) 匹多莫德治疗炎症性肠病的用途
HK40006674A (zh) 用於治疗疾病之神经醯胺半乳糖基转移酶抑制剂
UA91650U (uk) Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул
TN2015000431A1 (en) Use of pidotimod to treat irritable bowel syndrome
UA97983U (uk) Лікарська композиція для лікування захворювань суглобів

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2023 BY COMPUTER PACKAGES INC

Effective date: 20221117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2024 BY COMPUTER PACKAGES INC

Effective date: 20231117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2025 BY COMPUTER PACKAGES INC

Effective date: 20241117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2026 BY COMPUTER PACKAGES INC

Effective date: 20251126